DCP
ALXN

DSM Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

DSM Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-963
Closed -$134K – 66
2018
Q3 		$134K Hold
963
– – ﹤0.01% 51
2018
Q2 		$120K Hold
963
– – ﹤0.01% 50
2018
Q1 		$107K Sell
963
-757,246
-100% -$90.5M ﹤0.01% 48
2017
Q4 		$90.7M Sell
758,209
-651,941
-46% -$79.4M 1.26% 24
2017
Q3 		$198M Buy
1,410,150
+243,001
+21% +$33M 2.8% 15
2017
Q2 		$142M Buy
1,167,149
+153,233
+15% +$17.8M 2.11% 17
2017
Q1 		$123M Sell
1,013,916
-100,487
-9% -$13M 2.01% 21
2016
Q4 		$136M Sell
1,114,403
-51,224
-4% -$6.27M 2.36% 19
2016
Q3 		$143M Sell
1,165,627
-144,802
-11% -$18.6M 2.3% 19
2016
Q2 		$153M Sell
1,310,429
-53,154
-4% -$7.54M 2.63% 20
2016
Q1 		$190M Sell
1,363,583
-8,592
-0.6% -$1.26M 3.11% 14
2015
Q4 		$262M Buy
1,372,175
+124,788
+10% +$21.8M 4.1% 8
2015
Q3 		$195M Sell
1,247,387
-11,315
-0.9% -$2.06M 3.63% 9
2015
Q2 		$228M Buy
1,258,702
+322,305
+34% +$55.6M 3.88% 7
2015
Q1 		$162M Sell
936,397
-651,419
-41% -$118M 2.78% 16
2014
Q4 		$294M Sell
1,587,816
-10,220
-0.6% -$1.89M 5.42% 4
2014
Q3 		$265M Buy
1,598,036
+7,007
+0.4% +$1.15M 5.26% 2
2014
Q2 		$249M Buy
1,591,029
+563,868
+55% +$89M 5.05% 4
2014
Q1 		$156M Sell
1,027,161
-284,827
-22% -$45.3M 3.26% 13
2013
Q4 		$174M Buy
1,311,988
+257,523
+24% +$30.9M 3.49% 13
2013
Q3 		$122M Sell
1,054,465
-266,712
-20% -$29.3M 2.77% 19
2013
Q2 		$122M Buy
+1,321,177
New +$127M 3.03% 20

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DSM Capital Partners's ALXN Position: Q4 2018 in Review

DSM Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 963 shares — an estimated $134K sold.

DSM Capital Partners first reported a position in ALXN in Q2 2013 and held it in 22 quarters. The position peaked at $294M in Q4 2014. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • DSM Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • DSM Capital Partners sold 963 Alexion Pharmaceuticals shares in Q4 2018, an estimated $134K.
  • DSM Capital Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • DSM Capital Partners's Alexion Pharmaceuticals position peaked at $294M in Q4 2014.
  • 609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on DSM Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.